Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

AB Science: 100% response rate in phase 1 combination therapy against AML

AB Science reports that its drug AB8939, combined with venetoclax, produced a 100% partial response rate in four hard-to-treat AML patients (1 complete remission, 1 near-complete remission, 2 partial responses). The treatment was well tolerated with no hematologic or dose‑limiting toxicity. The company plans to complete the phase 1, start an expansion study with about 15 patients, and is in discussions with regulators; AB8939 has orphan drug status in the EU and USA. InvestingPro notes a market capitalization of USD 3.57 billion and classifies AB Science as undervalued in its proprietary fair‑value model. » More on de.investing.com
AB Science reports promising phase‑1 data in AML with AB8939

AB Science reports that the combination of AB8939 plus Venetoclax produced a 100% partial response rate in a phase‑1 study of three patients with refractory or relapsed acute myeloid leukemia, including a complete remission after the first 14‑day cycle. The combination appeared to be well tolerated with limited hematologic toxicity. The company plans an expansion study of around 15 patients, is evaluating designs for registrational trials, and estimates an addressable market of more than €2 billion per year. » More on de.investing.com
AB Science: positive early data for AB8939 plus Venetoclax in refractory AML

AB Science reports that in an ongoing phase‑1 study the first three patients with refractory/relapsed acute myeloid leukemia treated with AB8939 in combination with Venetoclax achieved a 100% partial response rate after 14 days; one patient reached complete remission. Two of the patients had previously progressed on Venetoclax‑based combinations. The combination was well tolerated with no reported hematologic toxicity; the program will now proceed with dose escalation followed by an expansion phase of about 15 patients. AB8939 has orphan drug status in the EU and US; the company plans a virtual expert meeting and expects further data on October 23, after analysts have already raised their estimates. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, AB Science has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, AB Science had revenue of €498k and net profit of -€9.03m

(EUR)	June 2026	YoY
Revenue	498k	-
Gross profit	-208k	-
Net profit	-9.03m	-
EBITDA	-10.32m	-

Fundamentals

Metric	Value
Market capitalization	€40.14m
Number of shares	73.25m
52-week high/low	€1.61 - €0.50
Dividends	No
Beta	1.23
P/E ratio	-6.81
PEG ratio	0.06
P/B ratio	-1.66
P/S ratio	34.69

Company profile

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.